This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2016
Latest funding
- $765,000
Towards optimization of anti-hormonal therapy in advanced prostate cancer
CIHR · 2019 · Principal investigator
- $638,775
Function of the glucuronosyltransferase pathway in chronic lymphocytic leukemia
CIHR · 2016 · Co-investigator
- $180,000
Identification of Novel Prognostic Biomarkers in Stem cell Transplantation and Prostate Cancer
CIHR · 2013 · Nominated PI
2 publications.
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
Petrylak DP, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, Todenhöfer T, Gurney H, Kramer G, Bergman AM, Zalewski P, De Santis M, Armstrong AJ, Gerritsen W, Pachynski R, Byun SS, Retz M, Levesque E, McDermott R, Bracarda S, Manneh R, Levartovsky M, Li XT, Schloss C, Poehlein CH, Fizazi K
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.
Saad F, Winquist E, Hubay S, Berry S, Assi H, Levesque E, Aucoin N, Czaykowski P, Lattouf JB, Alloul K, Stewart J, Sridhar SS
Towards optimization of anti-hormonal therapy in advanced prostate cancer
Principal investigators: Guillemette, Chantal; Levesque, Eric
Keywords: Anti-Androgens; Drug Metabolism; Metabolomics; Pharmacogenomics; Predictive Markers; Prostate Cancer; Steroids
Function of the glucuronosyltransferase pathway in chronic lymphocytic leukemia
Principal investigators: Guillemette, Chantal
Keywords: Cancer; Cll; Drug; Glucuronosyltransferase; Leukemia; Metabolism; Prognosis; Steroids; Treatment
Identification of Novel Prognostic Biomarkers in Stem cell Transplantation and Prostate Cancer
Principal investigators: Levesque, Eric
Keywords: Germline Variations; Graft-Vs-Host Disease; Immunosuppressants; Polymorphisms; Prognostic Biomarkers; Prostate Cancer; Stem Cell Transplantation; Steroid Hormones
Optimisation du traitement immunosuppresseur en transplantation de cellules souches hématopoïétiques chez les patients cancéreux.
Principal investigators: Laverdiere, Isabelle
Keywords: Cancers Hématologiques; Cellules Souches Hématopoïétiques; Immunosuppresseurs; Maladie Du Greffon Contre L'Hôte; Marqueurs Moléculaires; Monitoring Thérapeutique; Pharmacocinétique; Pharmacodynamie; Pharmacogénomique; Transplantation
HEMATOPOIETIC STEM CELL TRANSPLANTATION: IDENTIFICATION OF KEY DETERMINANTS OF GRAFT-VS-HOST DISEASE
Principal investigators: Levesque, Eric
Keywords: Cancer Therapy; Drug Metabolism; Graft-Vs-Host Disease; Hematology-Oncology; Immunogenetics; Molecular Biology; Pharmacogenomics; Stem Cell Transplantation
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Hematology-Oncology
- Clinical Pharmacology
- Internal Medicine
Co-authors at Université Laval, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.